Vertex Announces Planned Initiation of Phase 2 Studies Evaluating Next-Generation Correctors
FULL PRESS RELEASE HEREVertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis VX-440 to be evaluated as part of 4-week triple combination dosing with tezacaftor (VX-661) and ivacaftor;...